Background:
The objective of this multicenter study was to investigate the long -term preventive effect of chemoprophylaxis with low-dose fluoroquinolones and/or immunotherapy in women with recurrent UTI. Both Uro -Vaxom (OM -89) and Luivac are extracts of bacterial components with complex immunostimulating activity.
Methods & Materials: Adult female patients with at least 3 documented episodes of UTI in a previous year were enrolled in this 12 -months, multicenter study. Patients received continuous chemoprophylaxis with low -dose ciprofloxacin (125 mg orally every other day) and /or immunotherapy with either Uro-Vaxom or Luivac. Primary efficacy criteria were number of UTI episodes over the 12 months treatment period.
Results: A total of 178 patients were treated, 89 in the Uro -Vaxom and 89 in the Luivac group, respectively. Mean rate of post baseline UTIs decreased significantly in both treatment groups: in Uro -Vaxom group from 3.54 to 0.48 episode / patient / year and in Luivac group from 3.63 to 0.41 episode /patient/ year (p < 0.001). There were 67.1% patients treated with combination of immunotherapy and quinolone prophylaxis vs. 52.7% patients treated with immunotherapy only, who were UTI -free in 12 -months study period (p = 0.04). In the subgroup receiving continuous antimicrobial prophylaxis with ciprofloxacin (125 mg orally every other day), selection of quinolone -resistant strains was observed in 9 patients (ESBL -producing strains of E. coli and Klebsiella pneumoniae). After 5-years follow -up, there remained 65.0% patients UTI -free in this study period.
Conclusion: These results confirm that immunotherapy is more safe and almost as effective as low-dose quinolone prophylaxis in prevention of recurrent UTI. Selection of quinolone -resistant strains is a potential threat for patients on long-term quinolone prophylaxis.
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